T-loop phosphorylated Cdk9 localizes to nuclear speckle domains which may serve as sites of active P-TEFb function and exchange between the Brd4 and 7SK/HEXIM1 regulatory complexes-Reference-Cited by-同舟云学术

T-loop phosphorylated Cdk9 localizes to nuclear speckle domains which may serve as sites of active P-TEFb function and exchange between the Brd4 and 7SK/HEXIM1 regulatory complexes

Published:2010 Issue: Volume: Page:n/a-n/a
ISSN:0021-9541
Container-title:Journal of Cellular Physiology
language:en
Short-container-title:J. Cell. Physiol.

Author:

Dow Eugene C.,Liu Hongbing,Rice Andrew P.

Publisher

Wiley

Subject

Cell Biology,Clinical Biochemistry,Physiology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jcp.22096/fullpdf

Reference53 articles.

1. Interplay between 7SK snRNA and oppositely charged regions in HEXIM1 direct the inhibition of P-TEFb;Barboric;EMBO J,2005

2. The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation;Baumli;EMBO J,2008

3. Rules of engagement: Co-transcriptional recruitment of pre-mRNA processing factors;Bentley;Curr Opin Cell Biol,2005

4. Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex;Biglione;Retrovirology,2007

5. Cytostellin distributes to nuclear regions enriched with splicing factors;Bregman;J Cell Sci,1994

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rapid P-TEFb-dependent transcriptional reorganization underpins the glioma adaptive response to radiotherapy;Nature Communications;2024-05-30

2. The cell biology of HIV-1 latency and rebound;Retrovirology;2024-04-05

3. Phase Separation: Direct and Indirect Driving Force for High-Order Chromatin Organization;Genes;2023-02-15

4. New insights into transcription elongation control of HIV-1 latency and rebound;Trends in Immunology;2023-01

5. VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia;Leukemia;2022-11-14